Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358163 · ClinicalTrials.gov registry record · Phase 1
Trial of PTK787/ZK 222584 Plus Paclitaxel
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00358163 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 7 participants.
The verdict
NCT00358163, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
PTK787/ZK 222584 is an inhibitor of VEGFR family tyrosine kinases. The primary objective of this study is to assess the safety of daily oral PTK787/ZK 222584 in combination with paclitaxel infused every 21 days. Secondary objectives include pharmacokinetic assessment of the impact of PTK787/ZK 222584 on paclitaxel metabolism and evaluation of tumor response to the investigational treatment.
Interventions
- DRUG paclitaxel
- DRUG PTK787/ZK 222584
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2006-04-26 |
| Est. Completion | 2008-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00358163
The ClinicalTrials.gov registry entry for NCT00358163 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00358163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00358163 about?
NCT00358163 is a clinical study titled "Trial of PTK787/ZK 222584 Plus Paclitaxel". PTK787/ZK 222584 is an inhibitor of VEGFR family tyrosine kinases. The primary objective of this study is to assess the safety of daily oral PTK787/ZK 222584 in combination with paclitaxel infused every 21 days. Secondary objectives include pharmacokinetic assessment of the impact of PTK787/ZK 22258...
What is the current status of trial NCT00358163?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2006-04-26. Estimated completion is 2008-05-29.
What interventions are being tested in trial NCT00358163?
The interventions under investigation include: paclitaxel (DRUG), PTK787/ZK 222584 (DRUG).
Who is sponsoring clinical trial NCT00358163?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.